Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus

Journal of Infection

Volumn 67, Issue 3, 2013, Pages 215-219

  Hata, Atsuko ^a   Inoue, Fukue ^a   Yamasaki, Midori ^a   Fujikawa, Jun ^a   Kawasaki, Yukiko ^a   Hamamoto, Yoshiyuki ^a   Honjo, Sachiko ^a   Moriishi, Eiko ^b   Mori, Yasuko ^b,c   Koshiyama, Hiroyuki ^a  

^a Kitano Hospital   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell mediated immunity (CMI); Diabetes mellitus; Herpes zoster; Immunogenicity; Live Oka varicella vaccine; Safety

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION TEST; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INTERVENTION STUDY; JAPAN; MALE; PILOT STUDY; PRURITUS; QUESTIONNAIRE; SKIN TEST; SYSTEMIC DISEASE;

CELL-MEDIATED IMMUNITY (CMI); DIABETES MELLITUS; HERPES ZOSTER; IMMUNOGENICITY; LIVE OKA VARICELLA VACCINE; SAFETY;

AGED; ANTIBODIES, VIRAL; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION TESTS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PILOT PROJECTS; SKIN TESTS;

EID: 84881029480     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.04.010     Document Type: Article

References (21)

1. Cohen J.I., Brunell P.A., Straus S.E., Krause P.R. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999, 130:922-932.
2. Vaccines 2013, W.B. Saunders Company, Philadelphia. 6th ed. S.A.O.W.A. Plotkin, P.A. Offit (Eds.).
3. Izawa T., Ihara T., Hattori A., Iwasa T., Kamiya H., Sakurai M., et al. Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 1977, 60:805-809.
4. Takahashi M., Okada S., Miyagawa H., Amo K., Yoshikawa K., Asada H., et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003, 21:3845-3853. 10.1016/S0264-410X(03)00303-7.
5. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
6. Rafael Harpaz M.I.R.O.-S., Seward J.F. Prevention of herpes zoster, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30.
7. Gnann J.W., Whitley R.J. Clinical practice. Herpes zoster. NEngl J Med 2002, 347:340-346.
8. Hata A., Kuniyoshi M., Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 2011, 39:537-544.
9. Okamoto S., Hata A., Sadaoka K., Yamanishi K., Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009, 200:1606-1610.
10. Asano Y., Shiraki K., Takahashi M., Nagai H., Ozaki T., Yazaki T. Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis 1981, 143:684-692.
11. Sadaoka K., Okamoto S., Gomi Y., Tanimoto T., Ishikawa T., Yoshikawa T., et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008, 198:1327-1333.
12. Yamada A., Ogino S., Asano Y., Otsuka T., Takahashi M., Baba K., et al. Comparison of 4 serological tests - complement fixation, neutralization, fluorescent antibody to membrane antigen and immune adherence hemagglutination - for assay of antibody to varicella-zoster (V-Z) virus. Biken J 1979, 22:55-60.
13. Marin M., Guris D., Chaves S.S., Schmid S., Seward J.F. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-40.
14. Delamaire M., Maugendre D., Moreno M., Le Goff M.C., Allannic H., Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997, 14:29-34.
15. Calvet H.M., Yoshikawa T.T. Infections in diabetes. Infect Dis Clin North Am 2001, 15:407-421. viii.
16. Plouffe J.F., Silva J., Fekety R., Allen J.L. Cell-mediated immunity in diabetes mellitus. Infect Immun 1978, 21:425-429.
17. Heymann A.D., Chodick G., Karpati T., Kamer L., Kremer E., Green M.S., et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008, 36:226-230.
18. Nassaji-Zavareh M., Taheri R., Ghorbani R., Aminian M. Undiagnosed diabetes mellitus in patients with herpes zoster. Indian J Dermatol 2008, 53:119-121.
19. Donahue J.G., Choo P.W., Manson J.E., Platt R. The incidence of herpes zoster. Arch Intern Med 1995, 155:1605-1609.
20. Joesoef R.M., Harpaz R., Leung J., Bialek S.R. Chronic medical conditions as risk factors for herpes zoster. Mayo Clin Proc 2012, 87:961-967.
21. Ragozzino M.W., Melton L.J., Kurland L.T. Herpes zoster and diabetes mellitus: an epidemiological investigation. J Chronic Dis 1983, 36:501-505.